Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL.
Company profile
Ticker
AKRX, AKRXQ
Exchange
Website
CEO
Douglas S. Boothe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Advanced Vision Research, Inc. • Akorn (New Jersey), Inc. • Akorn Animal Health, Inc. • Akorn Ophthalmics, Inc. • Akorn Sales, Inc. • Inspire Pharmaceuticals, Inc. • Oak Pharmaceuticals, Inc. • Hi-Tech Pharmacal Co., Inc. • 10 Edison Street LLC • 13 Edison Street LLC ...
IRS number
720717400
AKRX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Oct 20
Latest ownership filings
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21
4
JOSEPH BONACCORSI
31 Aug 20
4
Randall E. Pollard
31 Aug 20
4
Jonathan Kafer
31 Aug 20
4
Duane A Portwood
12 May 20
4
Jonathan Kafer
12 May 20
4
JOSEPH BONACCORSI
12 May 20
4
Randall E. Pollard
12 May 20
SC 13G/A
BlackRock Inc.
8 May 20
4
JOSEPH BONACCORSI
6 May 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.87 mm | 83.87 mm | 83.87 mm | 83.87 mm | 83.87 mm | 83.87 mm |
Cash burn (monthly) | (no burn) | 8.42 mm | 31.48 mm | 41.94 mm | 3.21 mm | 2.98 mm |
Cash used (since last report) | n/a | 386.30 mm | 1.44 bn | 1.92 bn | 147.32 mm | 136.92 mm |
Cash remaining | n/a | -302.43 mm | -1.36 bn | -1.84 bn | -63.45 mm | -53.06 mm |
Runway (months of cash) | n/a | -35.9 | -43.2 | -43.9 | -19.8 | -17.8 |
Institutional ownership, Q3 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 500.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Markston International | 500.00 | $0.00 |